Cargando…

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma

BACKGROUND: In preclinical Ewing sarcoma (ES) models, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors were identified as a potential therapeutic strategy with synergy in combination with cytotoxic agents. This study evaluated the safety and dosing of the PARP1/2 inhibitor niraparib (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chugh, Rashmi, Ballman, Karla V., Helman, Lee J., Patel, Shreyaskumar, Whelan, Jeremy S., Widemann, Brigitte, Lu, Yao, Hawkins, Douglas S., Mascarenhas, Leo, Glod, John W., Ji, Jiuping, Zhang, Yiping, Reinke, Denise, Strauss, Sandra J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246769/ https://www.ncbi.nlm.nih.gov/pubmed/33289920 http://dx.doi.org/10.1002/cncr.33349

Ejemplares similares

Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells
por: Bridges, Kathleen A., et al.
Publicado: (2014)

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
por: Vormoor, Britta, et al.
Publicado: (2014)

SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy
por: Choy, Edwin, et al.
Publicado: (2018)

Corrigendum to “SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy”
por: Choy, Edwin, et al.
Publicado: (2019)

Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
por: Barazzuol, Lara, et al.
Publicado: (2013)

Overcoming Temozolomide Resistance in Glioblastoma via Enhanced NAD(+) Bioavailability and Inhibition of Poly-ADP-Ribose Glycohydrolase
por: Li, Jianfeng, et al.
Publicado: (2022)

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
por: Vitiello, Pietro Paolo, et al.
Publicado: (2021)

Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series
por: Gabrail, Nash, et al.
Publicado: (2020)

Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors.
por: Boulton, S., et al.
Publicado: (1995)

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide
por: Tentori, Lucio, et al.
Publicado: (2014)

Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies
por: Wang, Bi-Cheng, et al.
Publicado: (2022)

Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes
por: Gagné, Jean-Philippe, et al.
Publicado: (2008)

Molecular Bases of Catalysis and ADP-Ribose Preference of Human Mn(2+)-Dependent ADP-Ribose/CDP-Alcohol Diphosphatase and Conversion by Mutagenesis to a Preferential Cyclic ADP-Ribose Phosphohydrolase
por: Cabezas, Alicia, et al.
Publicado: (2015)

Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016)
por: Widemann, Brigitte C., et al.
Publicado: (2019)

Pancreatic β-Cell Death, Regeneration and Insulin Secretion: Roles of Poly(ADP-Ribose) Polymerase and Cyclic ADP-Ribose
por: Takasawa, Shin, et al.
Publicado: (2002)

Human mass balance study and metabolite profiling of (14)C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer
por: van Andel, Lotte, et al.
Publicado: (2017)

Poly(ADP-ribose): An organizer of cellular architecture
por: Leung, Anthony K.L.
Publicado: (2014)

Poly (ADP-ribose) in the pathogenesis of Parkinson's disease
por: Lee, Yunjong, et al.
Publicado: (2014)

RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015)

Oncogenic activity of poly (ADP-ribose) glycohydrolase
por: Marques, Maud, et al.
Publicado: (2018)

Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019)

The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021)

ARH Family of ADP-Ribose-Acceptor Hydrolases
por: Ishiwata-Endo, Hiroko, et al.
Publicado: (2022)

The PARP1 Inhibitor Niraparib Represses DNA Damage Repair and Synergizes with Temozolomide for Antimyeloma Effects
por: Shen, Hong-Yuan, et al.
Publicado: (2022)

Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers
por: Tesauro, Cinzia, et al.
Publicado: (2014)

Specific cyclic ADP-ribose phosphohydrolase obtained by mutagenic engineering of Mn(2+)-dependent ADP-ribose/CDP-alcohol diphosphatase
por: Ribeiro, João Meireles, et al.
Publicado: (2018)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

Stability of centrosome numbers in poly(ADP-ribose) polymerase-1- and poly(ADP-ribose) glycohydrolase-deficient mouse ES cells
por: Ogino, Hideki, et al.
Publicado: (2004)

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)
por: Kim, AeRang, et al.
Publicado: (2020)

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
por: Daniel, R A, et al.
Publicado: (2010)

Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
por: Ji, Jiuping, et al.
Publicado: (2011)

Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status
por: Genther Williams, Sybil M, et al.
Publicado: (2015)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

New Facets in the Regulation of Gene Expression by ADP-Ribosylation and Poly(ADP-ribose) Polymerases
por: Ryu, Keun Woo, et al.
Publicado: (2015)

Engineering Af1521 improves ADP-ribose binding and identification of ADP-ribosylated proteins
por: Nowak, Kathrin, et al.
Publicado: (2020)

Selective monitoring of the protein-free ADP-ribose released by ADP-ribosylation reversal enzymes
por: Kasson, Samuel, et al.
Publicado: (2021)

Molecular Insights into Poly(ADP-ribose) Recognition and Processing
por: Žaja, Roko, et al.
Publicado: (2012)

The Sound of Silence: RNAi in Poly (ADP-Ribose) Research
por: Blenn, Christian, et al.
Publicado: (2012)

Role of poly(ADP-ribose) polymerases in male reproduction
por: Celik-Ozenci, Ciler, et al.
Publicado: (2013)

Readers of poly(ADP-ribose): designed to be fit for purpose
por: Teloni, Federico, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_iog9pkq803h22bffegpadn2pdg